---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-218745"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:54:03.083225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q2 net loss $54.1M ($0.93/shr); ALBRIOZA launched in Canada; FDA PDUFA Sept 29

## Summary
- Net loss $54.1M vs $21.9M in Q2 2021; R&D $24.3M, G&A $30.0M; no product revenue.
- Cash & equivalents $206.7M at June 30, down from $255.2M at March 31, 2022.
- ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022.
- FDA AdCom meeting Sept 7, 2022; PDUFA decision date Sept 29, 2022 for ALS NDA.
- EU MAA under review; decision expected first half 2023; commercial prep underway.

## SEC filing metadata
- accession: 0001193125-22-218745
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312522218745/0001193125-22-218745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312522218745/d392710d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-218745
- JSON: https://secwatch.observer/filing/0001193125-22-218745.json
- Plain text: https://secwatch.observer/filing/0001193125-22-218745.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.